The DOI matches its Crossref record.
Galectin-3 in Patients with Heart Failure with Preserved Ejection Fraction: Results from the Aldo-DHF Trial
Open accessAbstract
Aims: Galectin-3 is a marker of myocardial fibrosis and mediates aldosterone-induced cardiovascular inflammation and fibrosis. Characteristics of galectin-3 and its response to spironolactone have not been evaluated in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to determine the association between galectin-3 levels and patient characteristics in HFpEF; to evaluate the interaction between spironolactone and galectin-3 levels; and to assess the association between galectin-3 and clinical outcomes. Methods and results: Aldo-DHF investigated spironolactone 25 mg once daily vs. placebo for 12 months in patients with NYHA class II–III, LVEF ≥50%, grade ≥ I diastolic dysfunction, and peakVO2 ≤ 25 mL/kg/min. Galectin-3 levels were obtained at baseline, and at 6 and 12 months. The association between baseline galectin-3, change in galectin-3, and all-cause death or hospitalization was evaluated, and the interaction between galectin-3 and treatment was assessed. Median baseline galectin-3 was 12.1 ng/mL. After multivariable adjustment, baseline galectin-3 inversely correlated with peak VO2 (P = 0.021), 6 min walk distance (P = 0.002), and Short Form 36 (SF-36) physical functioning (P = 0.001), and directly correlated with NYHA class (P = 0.007). Baseline NT-proBNP correlated with E/e’ velocity ratio (P ≤ 0.001), left atrial volume index (P < 0.001), and LV mass index (P = 0.009). Increasing galectin-3 at 6 or 12 months was associated with all-cause death or hospitalization independent of treatment arm [hazard ratio (HR) 3.319, 95% confidence interval (CI) 1.214–9.07, P = 0.019] and NT-proBNP (HR 3.127, 95% CI 1.144–8.549, P = 0.026). Spironolactone did not influence galectin-3 levels. Conclusion: Galectin-3 levels are modestly elevated in patients with stable HFpEF and relate to functional performance and quality of life. Increasing galectin-3 was associated with worse outcome, independent of treatment or NT-proBNP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1858 · Cited by 2,043
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Inflammation – Cause or Consequence of Heart Failure or Both?
Van Linthout, S., & Tschöpe, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0337-9 · Cited by 465
Self-citationGalectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)
Dong, R., Zhang, M., Hu, Q., Zheng, S., Soh, A., Zheng, Y., & Yuan, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3311 · Cited by 406
The fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
Role of Inflammation in Heart Failure
Shirazi, L. F., Bissett, J., Romeo, F., & Mehta, J. L. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0660-3 · Cited by 278
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling
Horn, M. A., & Trafford, A. W. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.005 · Cited by 275
De Marco, C., Claggett, B. L., de Denus, S., Zile, M. R., Huynh, T., Desai, A. S., Sirois, M. G., Solomon, S. D., Pitt, B., Rouleau, J. L., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13153 · Cited by 29
Metadata
- Authors
- Edelmann, F., Holzendorf, V., Wachter, R., Nolte, K., Schmidt, A. G., Kraigher-Krainer, E., Duvinage, A., Unkelbach, I., Düngen, H.-D., Tschöpe, C., Herrmann-Lingen, C., Halle, M., Hasenfuss, G., Gelbrich, G., Stough, W. G., & Pieske, B. M.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-24
- Volume
- 17
- Issue
- 2
- Pages
- 214-223
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W1893887535
- Cited by
- 176
- References
- 0
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.